WASHINGTON — A House committee on Wednesday passed a bill to renew a program aimed at aiding development of drugs for rare diseases in children, putting it in a better position to be added to government funding legislation.
The pediatric rare disease priority review voucher program is set to end on Sept. 30. The legislation would extend the program until Sept. 30, 2029.
The end of the third quarter is also the end of this year’s government funding cycle. To avoid a shutdown, Congress must either pass government funding by then or agree to temporarily continue this year’s funding while they work out a deal. The current outlook for government funding is murky.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.
Already have an account? Log in
